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Tri-ponderal mass index in survivors 
of childhood brain tumors: A cross-
sectional study
E. Danielle Sims1,2, Kuan-Wen Wang1,2, Adam Fleming1,3, Donna L. Johnston4, 
Shayna M. Zelcer5, Shahrad Rod Rassekh6, Sarah Burrow7, Lehana Thabane8,9,10,11 & 
M. Constantine Samaan1,2,8
Survivors of childhood brain tumors (SCBT) face a higher risk of cardiometabolic disorders and 
premature mortality compared to the general population. Excess adiposity is a known risk factor 
for these comorbidities. However, while SCBT have higher adiposity compared to healthy controls, 
measuring adiposity in clinical practice involves access to specialized equipment and may impact busy 
clinical services. Tri-ponderal Mass Index (TMI; kg/m3) may be a superior measure of adiposity when 
compared to Body Mass Index (BMI; kg/m2). However, its use in determining adiposity in SCBT has 
not been assessed. This study aims to validate TMI as a clinical measure of adiposity in SCBT. This was 
a cross-sectional study including 44 SCBT (n = 20 female) and 137 (n = 64 female) non-cancer control 
children, 5–17 years of age. BMI and TMI were calculated from height and weight measurements. 
Fat mass percentage was assessed using bioelectrical impedance analysis and waist to hip and waist 
to height ratios were used to assess central adiposity. Regression analyses were adjusted for age, 
sex, puberty and treatment. TMI demonstrated strong correlations to measures of total and central 
adiposity and predicted adiposity in SCBT and non-cancer controls, with stronger trends in the latter 
group. TMI may serve as a reliable clinical measure of adiposity in both SCBT and healthy children.
Obesity has contributed to the rise of cardiovascular diseases and type 2 diabetes, making them some of the most 
significant and costly healthcare challenges of the 21st century1–6. One group that is especially impacted by these 
chronic diseases include childhood cancer survivors7–9. Within this population, survivors of childhood brain 
tumors (SCBT) represent an emerging group that has been recently reported to develop stroke and type 2 diabetes 
at higher rates than those seen in non-cancer control populations10–12. Obesity leads to increased cardiovascular 
mortality at a relatively young age in SCBT12–22.
Excess adiposity, especially visceral adiposity, has been linked to cardiovascular disease and type 2 diabetes in 
the general population, and SCBT have more adiposity compared to healthy controls23–27.
While adiposity is a potentially modifiable risk factor for cardiometabolic risk, measuring adiposity in clinical 
practice can be time consuming in the clinical setting, and requires specialized equipment including bioelectrical 
impedance scales or Dual-energy X-ray Absorptiometry (DXA) scans28–30. The availability of feasible and reliable 
clinical measures of adiposity will circumvent these limitations and help prioritize SCBT for closer monitoring 
and targeting them in interventions in an attempt to improve outcomes.
The tri-ponderal mass index, defined as weight divided by height cubed (TMI, kg/m3), is an alternate measure 
of adiposity in children31. TMI is reported as a more accurate predictor of adiposity compared to Body Mass 
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Index (BMI, kg/m2) and BMI z-score when validated against DXA scans in adolescents31. An important advan-
tage of TMI is that it uses the same height and weight measurements used to calculate BMI. Thus, TMI may offer 
a feasible clinical measure to assess adiposity. However, TMI has not been validated as a measure of adiposity 
in SCBT. Our aim is to validate TMI as a clinical measure of adiposity in SCBT and compare this group to 
non-cancer controls.
Results
Population characteristics. The characteristics of participants are reported in Table 1. We included 44 
SCBT (n = 20 female, 45.50%), and 137 non-cancer controls (n = 64 female, 46.70%).
The SCBT and control groups had similar sex (p = 0.88) and ethnic distribution (Caucasian SCBT: n = 34 
(77.30%); controls: n = 91 (66.40%), p = 0.18). SCBT were younger than the non-cancer controls (SCBT: 
11.16 ± 4.29; controls: 14.03 ± 2.56, p < 0.001), and fewer survivors were pubertal compared to controls (SCBT: 
n = 23 (52.30%); controls: n = 121 (88.30%), p < 0.001). Survivors had lower weight (p < 0.001) and were shorter 
(p < 0.001) compared to controls.
In relation to body mass measures, we confirmed previous similar trends in both survivors and controls of 
BMI z-score (SCBT:0.57 ± 0.94; controls: 0.45 ± 1.12, p = 0.51) and BMI percentile (SCBT: 67.60 ± 26.30%; con-
trols: 62.20 ± 29.30%, p = 0.33).
Adiposity levels were similar between groups including fat mass percentage (%FM; SCBT: 24.10 ± 9.30%; 
controls: 22.20 ± 9.40%, p = 0.16) and waist-to-height ratio (WHtR) (SCBT: 0.46 ± 0.06; controls: 0.45 ± 0.07, 
p = 0.17). However, waist to hip ratio (WHR) was higher in SCBT when compared to non-cancer controls (SCBT: 
0.87 ± 0.07; controls: 0.82 ± 0.07, p < 0.001).
Due to the age and pubertal staging differences noted, we validated the results of the analysis of the full cohort 
by performing a subgroup analysis that included age- and sex-matched controls. In the latter analysis age, sex, 
and puberty adjusted analyses revealed identical trends to those reported for the full study cohort. The data for 
the matched subgroup analyses are reported in Supplementary Tables S1–S3.
Tumor characteristics and treatments.  The details of tumor characteristics and treatment methods are 
reported in Table 2.
The most common tumors in survivors were low-grade gliomas (n = 29 (65.90%)). Brain tumors were equally 
localized to supratentorial and infratentorial regions. The treatments included surgery (n = 29 (65.90%)), radio-
therapy (n = 13 (29.50%)) and chemotherapy (n = 20 (45.50%)). Eight (18.20%) participants were being managed 
with a wait and see approach at the time of inclusion in the study.
The association of TMI with body mass and adiposity. To assess if TMI correlates with body mass 
measures and adiposity, we used Spearman’s correlation test. We conducted unadjusted and age, sex, and 
puberty-adjusted analyses (Table 3).
TMI levels were similar between the groups (SCBT: 14.12 ± 2.54 kg/m3; controls: 13.46 ± 2.86 kg/m3, p = 0.10). 
TMI correlated with BMI z-score in both groups (Unadjusted, SCBT: ρ = 0.87; p < 0.001; controls: ρ = 0.95; 
p < 0.001; Adjusted, SCBT: r = 0.86; p < 0.001; controls: r = 0.94; p < 0.001).
We next assessed whether TMI correlates with measures of adiposity. TMI correlated significantly with meas-
ures of total adiposity including fat mass percentage (%FM) (Unadjusted, SCBT: ρ = 0.73; p < 0.001; controls: 
ρ = 0.85; p < 0.001; Adjusted, SCBT: r = 0.73; p < 0.001; controls: r = 0.88; p < 0.01). In addition, TMI correlated 
with measures of central adiposity, including WHR (Unadjusted, SCBT: ρ = 0.56; p < 0.001; controls: ρ = 0.38; 
p < 0.001; Adjusted, SCBT: r = 0.44; p < 0.01; controls: r = 0.46; p < 0.001), and WHtR correlated more strongly 
Variables
SCBT (n = 44) Controls (n = 137)
p-value (between groups)Mean ± SD Mean ± SD
Age at enrollment (years) 11.16 ± 4.30 14.03 ± 2.60 <0.001
Sex, No. (%)
   Male 24 (54.60) 73 (53.30)
0.88
   Female 20 (45.40) 64 (46.70)
Puberty
   Pre-pubertal 21 (47.70) 16 (11.70)
<0.001
   Pubertal 23 (52.30) 121 (88.30)
Height (cm) 141.80 ± 25.00 162.70 ± 15.00 <0.001
Weight (kg) 43.20 ± 22.40 59.20 ± 20.60 <0.001
BMI z-score 0.57 ± 0.94 0.45 ± 1.10 0.51
BMI percentile (%) 67.60 ± 26.30 62.20 ± 29.30 0.33
TMI (kg/m3) 14.10 ± 2.50 13.50 ± 2.90 0.099
Fat mass percentage 24.10 ± 9.30 22.20 ± 9.40 0.16
Waist-to-hip ratio 0.87 ± 0.07 0.82 ± 0.07 <0.001
Waist-to-height ratio 0.46 ± 0.06 0.45 ± 0.07 0.17
Table 1. Study Population Characteristics. Abbreviations: SCBT, survivors of childhood brain tumors; SD, 
standard deviation; BMI, body mass index; TMI, tri-ponderal mass index.
www.nature.com/scientificreports/
3SCIEnTIfIC REPORTS |         (2018) 8:16336  | DOI:10.1038/s41598-018-34602-5
with TMI when compared to WHR (Unadjusted, SCBT: ρ = 0.69; p < 0.001; controls: ρ = 0.83; p < 0.001; 
Adjusted, SCBT: r = 0.82; p < 0.001; controls: r = 0.87; p < 0.001). There were similar trends of correlations of 
TMI and BMI z-score with measures of central adiposity (Table 3). Taken together, the above data indicate that 
TMI is a stronger predictor of total adiposity than BMI z-score and is equivalent to BMI z-score in predicting 
central adiposity. The correlation between TMI and BMI z-score tended to be stronger in non-cancer controls 
compared to SCBT.
To assess whether TMI is a predictor of body mass and adiposity in SCBT, multivariable linear regression 
analyses were conducted adjusting for age, sex and puberty. As radiotherapy was a significant predictor of %FM 
(p = 0.002) in SCBT, it was also adjusted for in the regression analyses.
We calculated unstandardized (B) and standardized (β) coefficients, and both trended in the same direction. 
Moving forward, we report on the latter coefficient (Table 4).
TMI was a strong predictor of BMI z-scores in both SCBT and controls, with a stronger trend in the latter 
(SCBT: β = 0.867; p < 0.001; controls: β = 0.935; p < 0.001). TMI was a strong predictor of total adiposity (%FM) 
in both SCBT and controls (SCBT: β = 0.604; p < 0.001; controls: β = 0.819; p < 0.001). While it had lower cor-
relation with WHR, TMI was associated strongly with WHtR, and the strength of this association was higher in 
controls compared to SCBT (SCBT: β = 0.793; p < 0.001; controls: β = 0.880; p < 0.001).
Variables No. (%)
Brain tumor type
Non-NF-1, low grade glioma 18(40.90)
PNET/Medulloblastoma 8 (18.20)
NF-1, low grade glioma 9 (20.50)
CNS germ cell tumors 3 (6.80)
Subependymal giant cell astrocytoma 2 (4.50)
Ependymoma 2 (4.50)
Meningioma 1 (2.30)
Choroid plexus papilloma 1 (2.30)
Brain tumor location
Supratentorial 22 (50.00)
Infratentorial 22 (50.00)
Brain tumor treatments
Surgery 29 (65.90)
Radiotherapy 13 (29.50)
Chemotherapy 20 (45.50)
No treatment 8 (18.20)
Table 2. Brain tumor characteristics (n = 44). Abbreviations: CNS, Central Nervous System; PNET, Primitive 
Neuroectodermal Tumor; NF-1, Neurofibromatosis Type 1.
Group Variable BMI z-score %FM WHR WHtR
Unadjusted
SCBT
TMI 0.87** 0.73** 0.56** 0.69**
BMI z-score — 0.66** 0.55** 0.71**
Controls
TMI 0.95** 0.85** 0.38** 0.83**
BMI z-score — 0.80** 0.40** 0.81**
Total
TMI 0.93** 0.83** 0.45** 0.83**
BMI z-score — 0.78** 0.45** 0.80**
Partial Correlations - Adjusted for age, sex and puberty
SCBT
TMI 0.86** 0.73** 0.44* 0.82**
BMI z-score — 0.68** 0.46* 0.72**
Controls
TMI 0.94** 0.88* 0.46** 0.87**
BMI z-score — 0.90** 0.39** 0.80**
Total
TMI 0.92** 0.85** 0.46** 0.86**
BMI z-score — 0.85** 0.41** 0.78**
Table 3. Spearman’s correlation of TMI and BMI z-score with adiposity measures in SCBT and controls. 
*p-value < 0.05, **p-value < 0.001. Abbreviations: SCBT, survivors of childhood brain tumors; BMI, body mass 
index; TMI, tri-ponderal mass index; %FM, percent fat mass; WHR, waist-to-hip ratio, WHtR, waist-to-height 
ratio.
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The above threads of data indicate that TMI is a strong predictor of total adiposity and WHtR. The association 
between TMI and adiposity appears to be stronger in controls compared to SCBT for BMI z-score, %FM and 
WHtR.
Discussion
Survivors of childhood brain tumors are facing multiple comorbidities including cardiovascular disease and 
type 2 diabetes, which can impact their quality of life and lifespan13–15,27,32–36. The identification of predictors 
and markers of cardiometabolic risk may offer a path to stratify those in need of close observation and early 
intervention. In this study, we identified TMI as one such measure. TMI was an equally strong predictor as BMI 
z-score, total adiposity and WHtR, the latter being a stronger predictor of cardiometabolic risk compared to 
WHR37–39. As central adiposity is associated with adverse cardiometabolic outcomes37–40, this is of great clinical 
significance, as it allows the stratification of children with higher central adiposity to a care stream with closer 
cardiometabolic health monitoring and early more aggressive interventions.
TMI has been validated against DXA scan-measured adiposity in the general pediatric population31. Our data 
adds to the value of TMI in the general pediatric population and in a population with chronic health needs that 
has not been studied previously. TMI is a promising marker of adiposity that is clinically feasible and informative. 
The most widely used clinical measure of body mass, BMI, is a useful population-based measure to report the 
presence of obesity, and is used interchangeably to report adiposity41. However, one of the limitations of BMI is 
that it may not be adequate to diagnose obesity in certain populations, including adolescents42,43, hence the use 
of BMI z-score and percentile data to assess overweight and obesity in children. In addition, BMI misclassifies 
muscular individuals as being overweight or obese, which does not necessarily reflect their future risk of cardi-
ometabolic disorders44. Furthermore, BMI has a weaker association with cardiovascular risk when compared to 
measures of adiposity including waist circumference and WHtR37,45,46.
Children require special consideration in using BMI to classify obesity and adiposity. Ratios of weight over 
height to various powers of rho, ρ, (weight/heightρ) have been explored to account for the effects of children’s 
growth during puberty, and the adjustment for ρ is critical because incorrect values misclassify tall or physically 
advanced children as overweight47,48. A ρ value equal to two as used in BMI is sufficient when height is constant, 
however during puberty changes in height increase the ρ value48.
In pre-school children, weight over height squared is adequate for assessing adiposity47. Adiposity generally 
declines between the ages 5–7 years before it begins to rise again, the adiposity rebound phase49. An earlier adi-
posity rebound than expected is associated with an increased risk of obesity and type 2 diabetes in adults49–51.
As children approach the peripubertal phase of growth and development, their body composition changes 
with increased adiposity, especially in girls52,53. The value of ρ gradually rises from two to three; children who 
have undergone a growth spurt due to puberty tend to be heavier when compared to less mature children at the 
same height47. The increase in weight accompanying growth spurts results in higher BMI values, therefore greater 
values of ρ are required to offset the weight gain experienced in physically advanced children.
Variable Population
Standardized 
coefficient β p-value
Model Summary
Adjusted R 
Square
SE of the 
Estimate
Dependent Variable: BMI z-score
TMI
SCBT 0.867 <0.001 0.71 0.50
Controls 0.935 <0.001 0.88 0.38
Dependent Variable: %FM
TMI*
SCBT 0.604 <0.001 0.65 0.10
Controls 0.819 <0.001 0.81 0.09
BMI z-score*
SCBT 0.584 <0.001 0.65 0.10
Controls 0.836 <0.001 0.83 0.08
Dependent Variable: Waist-to-hip ratio
TMI
SCBT 0.425 0.004 0.20 0.03
Controls 0.436 <0.001 0.31 0.03
BMI z-score
SCBT 0.442 0.002 0.23 0.03
Controls 0.370 <0.001 0.25 0.03
Dependent Variable: Waist-to-height ratio
TMI
SCBT 0.793 <0.001 0.67 0.03
Controls 0.880 <0.001 0.77 0.03
BMI z-score*
SCBT 0.657 <0.001 0.58 0.03
Controls 0.804 <0.001 0.64 0.04
Table 4. Linear regression analyses of TMI in SCBT and controls adjusted for age, sex and puberty 
Abbreviations: SCBT, survivors of childhood brain tumors; BMI, body mass index; %FM, fat mass percentage; 
SE, standard error. Models were adjusted for age, sex and puberty. *Radiotherapy emerged as a significant 
predictor of adiposity, therefore we included it in the analysis.
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However, body composition changes in children become more constant as they get older and ρ decreases back 
to two47,48. Therefore, during puberty, TMI may be a more accurate measure of adiposity in children47. For this 
reason, the use of TMI is more relevant to assess body fat mass in children and, when evaluated in adults, TMI is 
less reliable compared to BMI when correlated with skinfold thickness41.
Measures of adiposity in children have relied on technologies that may not be readily available in the clinical 
setting but have demonstrated accuracy in estimating the fat mass. DXA estimates of trunk and abdominal fat 
have demonstrated a strong association to total abdominal fat28–30, while Bioelectrical impedance analysis (BIA) 
has been validated as a measure of adiposity against DXA54–56. Our results demonstrate that TMI is a strong 
predictor of adiposity measured using BIA, which is congruent with adiposity assessments using DXA. This is 
another strength of this study, as it validates TMI against BIA, a common measure of adiposity that is more easily 
accessible than DXA.
Our results indicate that TMI may offer a better estimate of fat mass and is a potential tool for predicting adi-
posity in children compared to BMI z-score. While some studies have found TMI to be an appropriate measure of 
adiposity in children, others have suggested BMI may still be an equivalent measure31,57. However, these studies 
often include children as young as two years of age, and weight scales over height squared in this age group that 
makes validating TMI as a measure of adiposity in this group a future goal of research47,57.
There are several strengths of our study. The inclusion of non-cancer controls for comparison to the SCBT group 
offers validation of this measure in the general pediatric population as well as SCBT. The description of the asso-
ciation of TMI with measures of central adiposity is another strength, as central adiposity is not routinely assessed 
in clinical practice. Furthermore, the inclusion of an age and sex matched subgroup analysis validates our findings.
A larger sample size of SCBT is required to validate these results further, and to define their associations. In 
addition, TMI needs to be validated as a predictor of cardiometabolic outcomes which should be part of longitu-
dinal studies.
In conclusion, TMI represents a clinically feasible measure that uses the same variables measuring BMI but 
demonstrate higher correlation with adiposity.
The availability of TMI as a clinical measure of adiposity will allow the stratification of patients at risk of excess 
adiposity to be prioritized for targeted interventions. This is critical, as these survivors are facing cardiometabolic 
diseases that are important emergent determinants of outcomes.
Methods
Participants. Participants were consecutively recruited from McMaster Children’s Hospital (Hamilton), 
Ontario, Canada from November 2012 to November 2017 to partake in the Canadian Study of Determinants of 
Endometabolic Health in Children (CanDECIDE study)58,59.
Children between 5–17 years of age were included. Parental informed consent was obtained for participants 
less than 7 years of age, and parental consent and participant assent were obtained for those 7–15 years of age. 
Participants provided written informed consent if they were 16 years or older. This is a secondary analysis of the 
CanDECIDE cohort study data and this analysis has been approved by the Hamilton Integrated Research Ethics 
Board. Study procedures were performed in accordance with the relevant guidelines and legal regulations.
Anthropometric and clinical measurements. Standardized questionnaires were used to collect data on 
age, sex, puberty, and ethnicity58,59. Medical records were consulted to verify and collect data regarding tumor 
type, location, sidedness and treatment modalities for SCBT.
Anthropometric measurements included weight measured to the nearest 0.1 kg using an electronic weighing 
scale (Seca, USA) and height using a stadiometer measured to the nearest 0.1 cm. BMI (kg/m2) and TMI (kg/m3) 
were determined using height and weight measurements from all participants. BMI percentile was determined 
from the Children’s BMI Tool for Schools60. BMI z-scores were determined from the Centers for Disease Control 
and Prevention (CDC) growth chart61.
Fat mass percentage (%FM) was used to determine adiposity in the participants that was measured with the 
Tanita body fat monitor (Tanita Corporation, Illinois, USA)62.
Statistical Analysis. Statistical analyses were performed using PASW version 18 statistical package63. Data 
are presented as counts with percentages for categorical variables and means with standard deviation for continu-
ous variables. Only participants with complete datasets were included. Box plots and visual inspection were used 
to identify any outliers for removal from the analysis. Normality of the data distribution was assessed using the 
Shapiro-Wilk test64. In the case that variables had non-normal distributions, data were log-transformed. Sample 
size was calculated using the method proposed by Norman and Streiner. We calculated that we need eight subjects 
per variable to detect significant differences between groups65.
Spearman’s correlations were used to assess the relationship between TMI, BMI z-score, %FM, WHR and WHtR. 
To assess this relationship adjusted for age, sex and puberty, we ran a Partial Correlations test. Multivariable linear 
regression analyses were performed to determine the association between TMI with BMI z-score and adiposity 
measures (%FM, WHR and WHtR), in SCBT and controls. The dependent variable was set as %FM, WHtR, WHR 
or BMI z-score and the independent variables included TMI, age, sex, puberty and treatment. Results were reported 
as standardized β coefficients and associated p-values, with statistical significance set to alpha of 0.05. A model sum-
mary, including the adjusted R Square and the Standard Error of the Estimate, were also reported.
In order to validate that age and puberty differences did not affect the results, analyses were also repeated 
using an age- and sex-matched control group. Control participants were matched in terms of sex distribution to 
SCBT participants on a one-to-one ratio and age was matched to closest value, within three years of the SCBT 
participants.
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Data Availability
The data for the current study used for statistical analysis are available from the corresponding author upon rea-
sonable justification.
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